Fyfe2 H1n1 Presentation Sept 22 09 For Posting

Uploaded on

Influenza A H1N1 VIHA Family Practice Rounds

Influenza A H1N1 VIHA Family Practice Rounds

More in: Travel , Technology
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Influenza A H1N1 Murray Fyfe September 22, 2009 VIHA Family Practice Rounds
  • 2. Clinical Presentation of Initial US H1N1 Cases fever cough sore throat Additional symptoms: headache, coryza, diarrhea myalgia, arthralgia, fatigue and weakness vomit 0 20 40 60 80 100 percent of cases
  • 3. Majority (73%) of those hospitalized have one more underlying condition (e.g. respiratory, cardiac, metabolic, immunosuppressed, pregancy)
  • 4. H1N1 Basic Epidemiology • Incubation period: 1-7 days (likely up to 4) • Period of communicability: ~ 7 days • Secondary attack rate: 8-19% • Mode of transmission – Droplet spread – Aerosolization with certain procedures
  • 5. Surveillance Plan for H1N1 • Detailed data collection from all hospitalized cases • Lab based surveillance of all submitted specimens • Sentinel physicians • MSP data monitoring • Reporting of high absenteeism in schools/daycares • Active follow up with remote First Nations communities
  • 6. H1N1 Vaccine • Produced by GlaxoSmithKline • Adjuvanted (AS03) single Ag, split virus • Initial trials safe and immunogenic after single dose (similar vaccines from other manufactures showing similar results) • Initial shipments expected in mid- November; then weekly for about 2 months
  • 7. H1N1 Vaccine Priority Groups – persons with chronic medical conditions – pregnant women – children 6 months to less than 5 years of age – persons residing in remote and isolated settings or communities – health care workers involved in pandemic response or who deliver essential health services – household contacts or caregivers of those at high risk who cannot be immunized – populations otherwise identified as high risk
  • 8. H1N1 Vaccine Delivery • Expected to start in mid-November • Physician and public health delivered – Physicians will have a critical role in providing to their patients in a timely way • 10 dose vials – e.g. could plan for 10 patients in ½ hour block • IM injection (likely single dose) • Further information including ordering forms will be sent by mail in October.
  • 9. Tamiflu • Commercial supply currently available through community pharmacies • Provincial stockpile to be released to community pharmacies Oct 1. • Available with physician prescription – Consider providing high risk patients a prescription in advance that could be filled during fall if they develop influenza
  • 10. Tamiflu Indictions • Early treatment of influenza in: – patients with underlying conditions:, respiratory, cardiovascular disease, diabetes, obesity, immunocompromised – Pregnancy – Children 2 years and under – *Aboriginal people living on reserve • Treatment of severe influenza cases
  • 11. H1N1 Communications • Public: – General mild level of illness – Self isolation, cough etiquette, hygeine – Info on self care • Physicians – Provincial Health Officer emailed notices – VIHA MHO letters – NEW fax distribution – VIHA website